SEC Filings

SEC Filings

Filing date	Description	Form	View
Oct 01, 2019	An amendment to the SC 13G filing	SC 13G/A	View HTML 0000921895-19-002479.pdf 0000921895-19-002479.rtf 0000921895-19-002479.xls
Sep 30, 2019	Report of unscheduled material events or corporate event	8-K	View HTML 0001104659-19-051877.pdf 0001104659-19-051877.rtf 0001104659-19-051877.xls
Sep 30, 2019	An amendment to a SC 13D filing	SC 13D/A	View HTML 0000919574-19-006120.pdf 0000919574-19-006120.rtf 0000919574-19-006120.xls
Sep 25, 2019	Statement of changes in beneficial ownership of securities	4	View HTML 0000919574-19-006028.pdf 0000919574-19-006028.rtf
Sep 19, 2019	Statement of changes in beneficial ownership of securities	4	View HTML 0000919574-19-005951.pdf 0000919574-19-005951.rtf
Sep 11, 2019	Report of unscheduled material events or corporate event	8-K	View HTML 0001558370-19-008559.pdf 0001558370-19-008559.rtf 0001558370-19-008559.xls
Sep 04, 2019	Statement of changes in beneficial ownership of securities	4	View HTML 0000919574-19-005687.pdf 0000919574-19-005687.rtf
Aug 29, 2019	Statement of changes in beneficial ownership of securities	4	View HTML 0000919574-19-005603.pdf 0000919574-19-005603.rtf
Aug 19, 2019	Quarterly report which provides a continuing view of a company's financial position	10-Q	View HTML 0001558370-19-008251.pdf 0001558370-19-008251.rtf 0001558370-19-008251.xls EX-101.INS - EX-101.INS
Aug 15, 2019	Notification that form type 10-Q will be submitted late	NT 10-Q	View HTML 0001558370-19-008211.pdf 0001558370-19-008211.rtf 0001558370-19-008211.xls

Data provided by Kaleidoscope.

For investor inquiries, please contact:

ReShape Lifesciences Investor Contact:
Thomas Stankovich
Chief Financial Officer
949-276-6042
ir@ReShapeLifesci.com

Investor Contacts:
Rx Communications Group
Michael Miller
917-633-6086
mmiller@rxir.com

PRINT PAGE

EMAIL PAGE